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Abstract
Background: Mitochondrial disorders belong to the most prevalent inherited metabolic diseases with the
m.3243A > G mutation reflecting being one of the most common mutations in mitochondrial DNA. Previous
studies showed little relationship between mitochondrial genetics and disease manifestation. Relationship
between genotype and disease manifestation with patient reported quality of life and other patient reported
outcomes is still unexplored.
Methods: Seventy-two out of the 122 invited adult patients with m.3243A > G mutation completed online
standardized questionnaires on quality of life, functional impairment, fatigue and mental health as assessed by the
RAND-SF36, the Sickness Impact Profile (SIP), the Checklist Individual Strength (CIS) and the Hospital Anxiety and
Depression scale (HADS). Data were related to clinical manifestation reflected by the Newcastle Mitochondrial
Disease Adult Scale (NMDAS) score and heteroplasmy levels of the mutation in urine epithelial cells.
Results: Patients reported impaired quality of life. Sixty percent showed severe levels of fatigue, and 37 % showed
clinical relevant mental health problems, which was significantly more than healthy norms. These patient reported
health outcomes showed negligible relationship with levels of heteroplasmy (r = <.30) and weak (.30 < r < .50) to
moderate (.50 < r < .70) relationship with clinical manifestation.
Conclusions: Patient reported outcomes on quality of life, fatigue and mental health problems, are only partly
reflected by clinical assessments. In order to support patients more effectively, integration of patient reported
outcomes, alongside symptoms of their disease, in clinical practice is warranted.
Keywords: Mitochondrial disease, m.3243A > G mutation, Quality of life, Patient reported outcomes, Fatigue, Mental
health, Participation
Background
Mitochondrial disorders, as a group, belong to the most
prevalent inherited metabolic diseases. The incidence of
congenital mitochondrial disorders based on oxidative
phosphorylation (OXPHOS) defects is at least 1:8500 of
all life births [1]. Mitochondrial diseases can result from
mutations in either nuclear or mitochondrial DNA and
show great variability in expression. Although new
pharmacological interventions are being explored in cells
and animals, currently no cure or substantially alleviating
therapy is available for these disorders and care is focused
on alleviating the broad range of symptoms of the disease.
Mitochondrial diseases have a complex and heterogeneous
expression with often more than one system structurally
and/or functionally affected (e.g. brain, muscles, the heart).
Previous studies showed little relationship between mito-
chondrial genetics and clinical manifestation [2–5]
(Chinnery et al. 1997; Grady et al. 2014; De Laat et al.
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2012; Koene et al. 2013). In addition, a recent study
that took patient reported outcomes on fatigue into
account reported little relationship between these out-
comes and genotype and clinical manifestation either
[6] (Gorman et al. 2015). Information about patients’
self reported quality of life and impact of the disease
in their daily life is important to be able to focus care
on patients’ most important complaints, as well as to
further understand the relationship of biological and
clinical parameters with these patient reported
outcomes.
In a study of 78 parents of children with a mitochon-
drial disorder, Koene et al. showed in 2013 that the most
burdensome complaints of patients included fatigue,
problem behavior, muscle weakness and a high degree of
limitations in daily activities [5] (Koene et al., 2013). Re-
cently, Gorman et al. [6] (2015) supported the import-
ance of fatigue in a group of patients with a variety of
mitochondrial disorders.
This is in line with studies in patients with other chronic
conditions such as T1DM [7], multiple sclerosis [8], and
Ehlors-Danlos syndrome [9] showing fatigue as an import-
ant burden. These studies too, show little relationship of
patient reported outcomes such as fatigue and quality of
life with clinical manifestation. The aim of the present
study is to investigate patient reported outcomes in terms
of quality of life, functional impairment, fatigue and
mental health. In addition, this study is aimed to assess
the relationship between these patient reported outcomes
and disease manifestation as well as genotype.
We focused on a group of patients with the m.3243A >G
mutation reflecting one of the most common genetic
causes for mitochondrial disorders, often referred to
as acronym Mitochondrial Encephalomyopathy Lactic
Acidosis and Stroke like episodes (MELAS) [10] (Pavlakis,
Phillips, DiMauro, De Vivo, & Rowland, 1984) and/or
MIDD (maternally Inherited Diabetes and Deafness). The
disease spectrum of patients with the m.3243A >G
mutation is multidimensional. Patients suffer from various
mainly neurological problems (such as stroke like episodes,
epilepsy, dementia, migraine, muscle pain or psychiatric
problems), but also from a broad range of other problems
importantly affecting their daily functioning.
Methods
Sample
All 122 patients, age 18 or above, with a mitochon-
drial disease due to the m.3243A > G mutation in leu-
cocytes, urinary epithelial cells and buccal mucosa,
under care of the Nijmegen Center for Mitochondrial
Disorders at the Radboud University Medical Centre,
were invited to participate in this longitudinal obser-
vational study.
Procedure
After given informed consent, patients received an email
with a link to a private, secure website that presented a set
of questionnaires that could be administered at home, at
time of first access or later. Patients were asked to
complete the total set of questionnaires within one week.
Assessments were repeated after two weeks (T2) and
three months (T3). Newcastle Mitochondrial Disorder
Assessment Scale [11] (Schaefer et al. 2006) was assessed
during clinical consultations.
Ethical committee
This study was approved by the local ethical committee
of the Radboud University Medical Centre, Nijmegen,
the Netherlands. All participants gave informed consent.
Instruments
Genotype was assessed in terms of heteroplasmy levels
in leucocytes, urine epithelial cells and in buccal mucosa.
Genotyping procedure has been performed as described
earlier [3] (De Laat et al. 2012).
Disease Manifestation was assessed by the Newcastle
Mitochondrial Disease Adult Scale [11] (NMDAS; Schaefer
et al. 2006). The NMDAS is a measure to monitor the clin-
ical expression of the disease and consists of the following
three sections: (1) Current functioning: general physical
functioning of the patient in the past four weeks (2) System
specific involvement to gain insight in the functioning of
individual organ-systems. (3) Current clinical assessment
gives insight in the current clinical status of the patient.
Details of assessment as well as inter rater reliability are
described previously [3] (De Laat et al. 2012).
We defined NMDAS scores of 1 to 5 as mild clinical
manifestation, scores 6 to 20 as moderate and scores above
20 as severe clinical manifestation.
Patient reported health outcomes were assessed by on-
line administered self-report on quality of life, functional
impairment, fatigue and mental health.
Quality of life was assessed with the RAND-36. The
RAND-36 assesses 7 dimensions of quality of life (physical
functioning, social functioning, emotional functioning,
general health status, perceived change in health status,
sleep problems and pain). Scores on different scales range
from 0 (maximum limitations) to 100 (optimal function-
ing). As reference group we used a Dutch norm group for
general population of men and women age 18 to 75 years
[12] (Van der Zee & Sanderman, 2012).
Functional impairment was assessed with the Sickness
Impact Profile (SIP; [13, 14]). The SIP, is aimed to assess
changes of conduct in everyday activities due to sickness
and assesses the following dimensions of functioning:
Sleep/rest, home management, mobility, social interaction,
ambulation, alertness and intellectual functioning, work
and recreation and pastime. Total scores ranged from 0 to
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5799 with higher scores reflecting more impairment.
Dutch norms are not available but scores of comparison
groups with same age and sex were used consisting of 90
health controls in a study with 94 patients with Multiple
Sclerosis [15] (Servaes et al. 2002).
Perceived fatigue severity was assessed with the fatigue
severity subscale of the Checklist Individual Strength [16]
(CIS; Vercoulen et al. 1999). The CIS is a questionnaire
with 20 items that can be scored on a seven-point Likert
scale. The CIS is designed to assess different dimensions
of fatigue: fatigue severity (8 items scores ranging from 8
to 56), concentration (5 items scores ranging from 5 to
35), motivation (4 items scores ranging from 4 to 28) and
physical activity (3 items, scores ranging from 3 to 21).
Higher scores indicate higher levels of fatigue, more con-
centration problems, less motivation and low levels of
physical activity. Studies indicated that the fatigue severity
subscale was best indicator of patient reported fatigue
related complaints. It consists of items like I feel fit, I feel
tired, I feel powerless, I am rested, to complete on a 7-
point Likert scale. A CIS-fatigue score of 35 or more was
used to identify severe fatigue in correspondence with
other studies [9, 15] (e.g. Servaes et al. 2002, Voermans
et al. 2010). The CIS has good reliability and is used to
assess perceived fatigue in several groups of patients with
various medical conditions.
Mental functioning was assessed with the Hospital
Anxiety and Depression scale [17, 18] (Dutch translation:
Spinhoven et al. 1997), measuring symptoms of anxiety
and depression. The HADS is specially designed to assess
symptoms of depression in people with medical condi-
tions by controlling for vital aspects of depression that
could easily interfere with symptoms of the disease and
showed good reliability and validity.
Statistics
Logarithmic transformations were performed on variables
with a skewness of >1. Data analysis was performed using
SPSS version 20.0. Descriptive statistics were used to de-
scribe the characteristics of the sample as well as patient
reported outcomes on quality of life, functional impair-
ment, fatigue and mental health. Correlational analyses
identified the main correlates of disease manifestation with
different aspects of patient reported health status. RAND-
36 score on physical functioning (RAND-36_PF), was used
as indication for physical quality of life. Total scores were
used for SIP, CIS and HADS as indication of functional
impairment, subjective fatigue and mental health. Correla-
tions lower than .30 were considered negligible, between
.30 and .50 low, between .50 and .70 moderate and
between .70 and .90 strong [19] (Hincle et al. 2003). Hier-
archical multiple regressions were performed to explore
the predictive value of genotype and clinical manifestation
for patient reported outcomes. Genotype and clinical
manifestation were first entered in the analyses, followed
by patient reported outcomes. As dependent variables we
focused on physical functioning, functional impairment,
fatigue and mental health.
Results
Response
A total of 122 patients with the m.3243A >G mutation
was invited to participate. Seventy-two patients completed
the questionnaires, a response rate of 59 %. Demographic
characteristics of the patients are summarized in Table 1.
Fifty nine percent were women. Differences between
response group and non response group could be
assessed on demographic and clinical characteristics.
Heteroplasmy levels did not differ between the two
groups (t = −.705; p = .482). The same was true for
NMDAS subscales 1 and 2. Non response group
showed significantly more problems on the NMDAS 3
subscale (t = 6.771; p = .021) and nearly significant more
problems on total NMDAS scale (t = 3.809; p = 0.053).
Age (t = −.641; p = .523), BMI (t = −1.754; p = .082) and
height (t = −1.208; p = .229) did not differ, however, non
responders had a lower weight (t = −2.114; p = .036).
Response rate on repeated assessment at T2 and T3 was
50 (69 %) and 48 (67 %) respectively. Correlations on out-
comes measures between T1 and T2 assessments varied
from .837 (functional impairment) to .922 (mental health).
Correlations between T1 and T3 assessments varied from
.761 (functional impairment) to .858 (physical functioning).
Genotype
Levels of heteroplasmy were assessed in Leucocytes
(mean 19 %; SD = 13; range 0–56)), urinary epithelial
Table 1 General characteristics of patients (n = 72) as well as
genotype and disease manifestation
Mean Median Range
Age (years) 45 46 19–67
BMI (kg/m2) 24 23 14–41
Length (in cm) 168 167 142–193
Weight (in kg) 68 67 35–113
Heteroplasmy level (%)
-leucocytes 19 13 0–56
-UEC 49 27 0–97
-buccal mucosa 34 18 0–73
NMDAS
−1 current functioning 8 7 0–43
−2 system specific involvement 6 5 0–26
−3 current clinical assessment 3 4 0–29
total NMDAS 17 16 0–98
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cells (UEC; mean 49 %; SD = 27; range 0–97) and buccal
mucosa (mean 34 %; SD = 18; range 0–73).
Disease manifestation
Mean NMDAS score was 17 (SD = 15) varying from 1 to
98, median 14.5. Twenty-one percent of the patients
showed mild symptoms, 50 % moderate and 29 % severe.
There were no asymptomatic patients in the sample.
Quality of life
Quality of life of patients with m.3243A >G mutation is
presented in Table 2. Data show impairment in all quality
of life domains. In comparison to age and sex matched
norm groups, scores on all dimensions deviated from
healthy people (t- values varied from −10,96 (General
health: p < .001) to −2.98 (Mental health; p = .004)).
Scores on the RAND-36 subscale physical functioning
indicated significantly more problems (mean 63,40)
compared to norm group of comparable age and sex
(mean 81.9; t-value −5.9; p < .001). Most limitations were
experienced in putting great physical efforts, 61 % of the
patients experienced serious impairments. About one
third of the patients experienced serious impairments
with climbing stairs and walking more than one kilo-
meter. One out of five indicated serious problems with
putting moderate physical efforts, carrying groceries or
stooping. Only a one out of about ten patients or less
indicated severe impairments with walking more than
500 m, climbing one stair or washing and dressing.
Functional impairment
Functional impairment was assessed with the eight dimen-
sions of the Sickness Impact Profile (SIP): Mean scores on
home management were 86.89 (SD = 86.5; M = 54; range
0–328), on work 30.89 (SD = 59.1; M= 0; range 0–265),
and on recreation 76.54 (SD = 71.7; M= 51; range 0–261)
reflecting more functional impairments compared to
healthy controls (t-values vary from 2.184; p = .032
(work) to recreation t = 8.016; p < .001).
74 % of the patients experienced no impairment in
mobility, 57 % no impairment in ambulation. Mean
mobility score was 39.5 (SD = 93; M = 0; range 0–2173),
mean ambulation score was 60.0 (SD = 91; M = 0; range
0–494). Patients show more impairments than healthy
comparison group (mobility t = 3.018; p = .004; ambulation
t = 5.405; p < .001). Thirty-nine percent % of the patients
experienced no impairments in alertness. Mean alertness
score was 127,10 (SD = 157; M = 75; range 0–664), this
was more than healthy controls (t = 16.36; p < .001).
Fatigue
The majority of the patients with a m.3243A > G muta-
tion reported abnormal levels of fatigue (78 %), 60 % re-
ported severe levels of fatigue (n = 43, 60 %). The mean
CIS fatigue score was 37.4 (SD 12.8, Table 3). Mean
CIS_fatigue score of healthy controls was 17.3 (SD =
10.1). Patients show a little bit less fatigue than patients
with MS (t = −1.832; p = .071) but less than patients with
chronic fatigue syndrome (t = −9.439; p < .001). Age and
gender did not differ between fatigued patients and non-
fatigued patients.
Mental functioning
Mental functioning was assessed with the HADS. Results
indicated that 26,4 and 31,6 % of the patients indicated
clinical relevant symptoms of respectively depression
and anxiety. 36,9 % scored above the cutoff of clinical
relevant levels of general distress. Comparing the patient
groups with healthy Dutch controls shows higher levels
of depression (t = 3,092; p = .003) as well as total symp-
tom scores in the patient group (t = 2,048; p = 0.44).
Scores on anxiety were comparable to healthy control
and better than a comparison group of general medical
patients (t = −2,378; p = .020) [18].
Relationship of patient reported outcomes with disease
manifestation (NMDAS)
To assess to what extend patient reported outcomes
were related to disease manifestation as indicated by
NMDAS, ANOVA’s were performed with three NMDAS
categories as factor and set of patient reported outcomes
Table 2 Quality of life (RAND-SF36) scores compared to norms
(n = 72)
Meana SD Norm group
Physical health 63.4 26.7 81.9
Social health 64.1 24.3 86.9
Physical role functioning 39.6 42.5 79.4
Emotional role functioning 69.4 40.2 84.1
Mental health 70.8 17.6 76.8
Vitality 49.0 18.8 67.4
Pain 68.3 25.9 79.5
General health 44.1 22.4 72.7
Experiences health change 43.1 21.1 52.4
aHigher scores reflect better quality of life
Table 3 Fatigue as assessed by CIS compared to norms
Mean SD Mean norms SD Patients vs norms
Perceived fatigue 37.4 12.8 17.3 10.1 t = 13.541**
Concentration 18.7 9.2 9.5 5.9 t = 8.525**
Motivation 14.8 6.3 7.9 4.1 t = 9.312**
Activity 11.9 6.0 6.6 4.5 t = 7.475**
total 82.8 30.6 41.5 19.1 t = 11.441**
** = p < .001
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as dependent variables. ANOVA’s indicated that scores
on physical functioning, functional impairment, fatigue
and mental health differed significantly between
NMDAS severity groups, with patients with worst clin-
ical manifestation indicating most physical problems,
most functional impairment, most fatigue and most
mental health problems (Table 4).
To assess the strength of the relationship between dis-
ease presentation and patient reported outcomes, spear-
man correlations between NMDAS subscale scores and
different patient reported outcomes were calculated. Cor-
relation of physical functioning, functional impairment, fa-
tigue, and mental health with three subscales and total
scale on NMDAS varies from strong (r > =.70) to negligible
(r < .30). Perceived physical functioning was most strongly
related with NMDAS scores with strong correlations with
the NMDAS 1 (rho = −.727) and total score (rho = −.714),
and moderate correlation with NMDAS 2 (rho = −.528)
and 3 (rho = −.574). Functional impairment was most
strongly related to NMDAS1 (rho = .665) and NMDAS3
(rho = .382). Fatigue is moderately correlated with NMDAS
1 (rho = .564) and total NMDAS (rho = .546), and weak
with NMDAS 2 (rho = .446) and 3 (rho = .344). Men-
tal health was only weakly correlated with NMDAS 1
(rho = .376), 2 (rho = .454) and total score (rho = .425).
The correlation between mental health and NMDAS
3 was negligible.
Prediction of physical functioning, participation, fatigue
and mental functioning
To explore which factors predicted patient perceived health
status, four aspects of perceived health were taken into ac-
count as outcomes in different regression analyses: physical
functioning, impairments in daily functioning, fatigue and
mental health. Hierarchical regression analyses were per-
formed in which mitochondrial genetics and clinical mani-
festation were entered in the first steps, and subsequently
physical functioning, functional impairment, fatigue and
mental health in the next steps. The correlations are
presented in Table 5.
A first hierarchical multiple regression analysis was per-
formed to predict physical functioning. Next to genotype,
clinical manifestation was entered as predictor. The
total model significantly predicted physical functioning
(F (2,65) = 28.174; p < .001; R2 = 0.468). Heteroplasmy
did not significantly explained variance in physical
function, after controlling for genotype, NMDAS signifi-
cantly added 45.0 % explained variance. In the total model,
NMDAS (Beta = −.671; p < .001) was a significant pre-
dictor of physical functioning.
A second hierarchical multiple regression analysis was
performed to predict functional impairment. Next to geno-
type and clinical manifestation, physical functioning was
entered as predictor. The total model significantly pre-
dicted functional impairment (F (3,64) = 22.617; p < .001;
R2 = 0.519). NMDAS (33,1 %) and physical functioning
(15.9 %), significantly added explained variance. In the total
model, only physical functioning (Beta = −.561; p < .001
was a significant predictors of functional impairment.
A third hierarchical linear regression was calculated to
predict perceived fatigue based on genotype, clinical func-
tioning, physical functioning, and functional impairment.
A significant regression equation of the total model was
found (F(4,63) = 29.461, p < .001), with an R2 of .655.
Genotype explained 7.3 % variance, after controlling for
genotype, NMDAS added another 9.0 %; physical func-
tioning another 32.7 %, and, after controlling for previous
factors, functional impairment added another 16.5 % of
the variance.
In the total model, heteroplasmy (Beta = .586; p = .053),
NMDAS (Beta = −.337; p = .002), physical functioning
(Beta = −.445; p < .001), and functional impairment
(Beta = .586; p < .001) significantly predicted perceived
fatigue.
A last hierarchical linear regression analysis was calcu-
lated to predict mental health, also based on genotype,
clinical manifestation, physical functioning, functional im-
pairment, and fatigue. A significant regression equation of
the total model was found (F (5,62) = 13.250; p < .001),
with an R2 of .531. Heteroplasmy explained 6 % of the
variance. After controlling for heteroplasmy, NMDAS
additionally explained 9.1 % of the variance, physical
functioning also 11.6 %, functional impairment 19.6 % and
fatigue 5.8 %. In the total model, functional impairment
(Beta = .396; p = .013) and fatigue (Beta = .412; p = .008)
significantly predicted mental health.
Discussion
Patients with the m.3243A >G mutation, experience im-
portant impairments in several domains of their health.
Sixty percent showed severe levels of fatigue, and 37 %
percent showed clinical relevant mental health problems.
The variation in quality of life, functional impairment,
fatigue and mental health could not be explained by level
of heteroplasmy in body fluids and only partly by disease
manifestation as indicated by NMDAS. This means that
patients with a comparable clinical presentation can have
Table 4 Patient reported outcomes by NMDAS categories mild
(1–5), moderate (6–20), severe (>20)
F valuea
Physical functioning 25.364**
Functional impairment 19.568**
Fatigue 25.364**
Mental functioning 5.701*
aStatistic of ANOVA; ** p < .001; * p < .05
Verhaak et al. Orphanet Journal of Rare Diseases  (2016) 11:25 Page 5 of 8
a substantial variation in the impact of the disease in their
daily life. In order to tailor treatment to complaints ex-
perienced by patients, integrating the perspective of the
atient in clinical assessment is warranted [19] (Hymans
2011). This is especially important in mitochondrial
diseases because of the chronic and disabling character of
the disease and because of the focus on care rather than
cure [20] (Wolters et al. 2013).
One of the explanations for the variation in patient
reported health could be related to specific behaviour in
response to the disease. For instance, being engaged in
daily activities positively effects physical condition by
being active, stimulates social functioning by being in
contact with other people and stimulates mental health
by increasing the possibility to experience positive events
(see e.g. Apabhai et al. 2011 [21]). From studies in
patients with other chronic medical conditions, such as
Parkinsons Disease [22] (Simpson et al. 2014), Multiple
Sclerosis [23, 24] (Trojan et al. 2007), Diabetes [7]
(Goedendorp et al. 2014), Ehlors Danlos [9] (Voermans
et al. 2010), Rheumatoid Artritis [26], COPD [27, 28]
(Vercoulen et al. 2008); and cancer [15] (Servaes et al.
2002), we know that psychological factors could play a
role in the explanation of these illness behaviours. Con-
cerns about impact of activities on physical functioning or
specific attributions regarding causes of complaints have
been shown to mediate relationship between disease char-
acteristics and daily functioning [29] (Lukkahatai et al.
2013). This could provide hope for patients as tailored
care to support patients in management of daily activities
could support their participation and so, indirectly, im-
prove their daily functioning. However, future studies are
needed to understand the specific role of these factors in
patients with mitochondrial diseases in general and with
m.3243A >G mutation more specifically.
This study included a broad range of patient reported
outcomes based on standardised measures also shown
to be sensitive for investigating these outcomes in other
patient groups. In addition, also genotype and disease
manifestation were taken into account reflecting the
broad range of disease manifestation from genotype, to
clinical phenotype, to daily functioning and perceived
health. Quality of life and patient reported outcomes
are only sporadically integrated in studies concerning
patients with mitochondrial diseases. Mitochondrial
diseases are characterised by a great variability in
expression. This even more supports the need for sys-
tematic assessment of patient reported outcomes. This
study focused on a relatively homogeneous group of
patients carrying the same mutation. Including also
patients with different diagnoses even increase this
variability. This makes it even more important to built
agreement on the conceptualisation and subsequent
assessment of patient reported outcomes in patients
with mitochondrial disease. Especially in small patient
groups such as patients with the m.3243A > G
mutation, agreement in outcome assessments could
importantly increase gain in knowledge on variability in
patient reported outcomes, and, even more important,
its possible predictors.
This study also revealed interesting information regard-
ing outcomes of clinical trials predominantly focusing on
medical outcomes. This study shows that, next to survival
rates and clinical manifestation, also patient perceived
functioning on different health domains is important to
explain the relevance of trial outcomes for patients’ daily
functioning. It could also explain the possible role of
psychological and behavioral mediators explaining the re-
lationship between disease manifestation and perceived
functioning [30, 31, 32] (Miller et al. 2010; Wolters et al.
2013, Zeltner et al. 2014).
Longitudinal research should shed more light on this
issue. It could explain the role of these mediators in
changes in perceived health. It could be highly assumed,
for instance, that coping and cognitions regarding som-
atic complaints are important mediators able to explain
variation in the relationship between disease activity and
patients’ complaints. Future studies should also include
more objective assessment of daily functioning e.g. exer-
cise tests and by using registrations of daily movements.
However, previous studies revealed that ambulation sub-
scale of the SIP, as used in the present study, highly
Table 5 Correlations (spearmans’s rho) between genotype, clinical presentation and patient reported functioning on different
domains N=72
Physical functioning
(RAND-SF36_PF)
Functional impairment
(SIP total)
Fatigue
(CIS perceived fatigue)
Mental health
(HADS total)
Genotype -.215 .178 .271* .225*
NMDAS total score -.714** .558** .546** .425**
Physical functioning -.695** -.663** -.504**
Functional impairment -.695** .743** .669**
Fatigue -.663** .743** .692**
Mental health -.504** .415** .692**
** p<.001; * p<.05
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correlates with physical fitness and objective physical ac-
tivity [16] (Vercoulen et al. 1999).
Another limitation is that absence of assessment of
nutrition. Especially because of the relatively low weight
of patients in the sample, low BMI could explain fatigue
and poor physical functioning. Future studies should
take nutrition and its effects on different domains of
quality of life into account [33] (Arrom et al. 2014).
Future research has to further elaborate the develop-
ment and efficient use of patient reported outcomes in
the practice of mitochondrial medicine, as specific tools
need to be validated for specific patient groups. Differen-
tiation has to be made between instruments assessing
general quality of life, disease specific complaints and
specific bodily symptoms [20,32,34] (Wolters et al. 2013;
Zeltner et al. 2014; Bann et al. 2015). Instruments
assessing general quality of life are needed to compare
outcomes of patients with mitochondrial disorders with
patients with other, more or less comparable medical
conditions. Disease specific measures could be used to
compare the impact of the disease of a specific patient
in relation to the whole patient group. These measures
are also useful as outcomes for clinical trials because of
their frequently reported higher sensitivity for chance.
Developing these measures for the field of mitochon-
drial medicine asks for integrating instruments available
in other patient groups with information from interviews
with patients to be able to point to specific quality of life
aspects for patients with a mitochondrial disease. One
could think about the specific burden of the inherited
aspect of the disease, the lack of tangible symptoms of the
disease in communicating about impairments in the social
environment, the unpredictable course, the possible lethal
character and the lack of control patients could have on
the symptoms they experience. These specific characteris-
tics need to be integrated in a mitochondrial disease
specific instrument to assess quality of life, or burden of
the disease.
Conclusions
This study showed that patients reported considerable im-
pairments in their quality of life and daily functioning. In
addition, it indicated the complexity of the relationship be-
tween patient reported outcomes, clinical manifestation as
well as genotype in patients with m.3243A >G mutation.
This point to the importance of integrating patient re-
ported outcomes in clinical assessment as well as clinical
trials to gain more understanding in the complexity of
factors explaining outcomes in these patients, as well as to
provide starting points for interventions to support
patients in the management of their disease.
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